Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
Dennis J. Slamon,Patrick Neven,Stephen Chia,Peter A. Fasching,Michelino De Laurentiis,Seock-Ah Im,K. Petrakova,Giulia Val Bianchi,Francisco J. Esteva,Miguel Martin,Arnd Nusch,Gabe S. Sonke,Luis de la Cruz-Merino,J. Thaddeus Beck,Xavier Pivot,Manu Sondhi,Yingbo Wang,Arunava Chakravartty,Karen Rodriguez-Lorenc,Tetiana Taran,Guy Jerusalem +20 more
TL;DR: In this paper, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrants alone in postmenopaugmentation.
read more
Abstract: Background In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopau...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Francesco Schettini,Francesco Schettini,Fabiola Giudici,Mario Giuliano,Mario Giuliano,Massimo Cristofanilli,Grazia Arpino,Lucia Del Mastro,Fabio Puglisi,Sabino De Placido,Ida Paris,Pietro De Placido,Sergio Venturini,Sergio Venturini,Michelino De Laurentis,Pierfranco Conte,Dejan Juric,Antonio Llombart-Cussac,Lajos Pusztai,Aleix Prat,Aleix Prat,Guy Jerusalem,Angelo Di Leo,Daniele Generali +23 more
TL;DR: CDK4/6i+ET combinations compared to ET alone improve OS independent of age, menopausal status, endocrine sensitiveness and visceral involvement, and should be preferred as upfront therapy instead of endocrine monotherapy.
89
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
D. Slamon,O. Lipatov,Zbigniew Nowecki,Nicholas P. McAndrew,Bozena Kukielka-Budny,Daniil Stroyakovskiy,Denise A Yardley,Chiun-Sheng Huang,P. Fasching,John Crown,Aditya Bardia,Stephen Chia,Seock-Ah Im,Manuel Ruiz-Borrego,S. Loi,Binghe Xu,Sara A. Hurvitz,Carlos Barrios,M. Untch,Rebecca L. Moroose,Frances Visco,Karen Afenjar,R. Fresco,Irene Severin,Yan Ji,Farhat Ghaznawi,Zheng Li,Juan Pablo Zarate,Arunava Chakravartty,Tetiana Taran,Gabriel Hortobagyi +30 more
TL;DR: Ribociclib plus an NSAI significantly improved invasive disease-free survival in HR-positive, HER2-negative early breast cancer.
89
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu,Yuze Wu,Bin Song,Ming Yi,Yuheng Yan,Qingtao Mei,Kongming Wu +6 more
TL;DR: This work summarizes recent advances in targeted therapy and immunotherapy in TNBC, with the aim of serving as a reference for the development of individualized treatment of patients with TNBC in the future.
87
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Michela Piezzo,Paolo Chiodini,Maria Antonietta Riemma,Stefania Cocco,Roberta Caputo,Daniela Cianniello,Germira Di Gioia,Vincenzo Di Lauro,Francesca Di Rella,Giuseppina Fusco,Giovanni Iodice,Francesco Nuzzo,Carmen Pacilio,Matilde Pensabene,Michelino De Laurentiis +14 more
TL;DR: This meta-analysis of randomized controlled trials (RCTs) is aimed to better characterize the efficacy of CDK4/6 inhibitors in some relevant subgroups and to test heterogeneity between different compounds with a particular focus on their ability to improve overall survival (OS).
Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.
TL;DR: In this paper , the authors discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance, including treatment algorithms based on current data.
80
References
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn,Miguel Martin,Hope S. Rugo,Stephen R. Jones,Seock-Ah Im,Karen A. Gelmon,Nadia Harbeck,Oleg Lipatov,Janice M. Walshe,Stacy L. Moulder,Eric Gauthier,Dongrui R. Lu,Sophia Randolph,Véronique Diéras,Dennis J. Slamon +14 more
TL;DR: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with let rozole alone, although the rates of myelotoxic effects were higher with palbokiclib-letrozoles.
2.4K
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn,John Crown,István Láng,Katalin Boér,Igor Bondarenko,Sergey O. Kulyk,Johannes Ettl,Ravindranath Patel,Tamás Pintér,Marcus Schmidt,Yaroslav Shparyk,Anu Thummala,Nataliya L. Voytko,Camilla Fowst,Xin Huang,Sindy T. Kim,Sophia Randolph,Dennis J. Slamon +17 more
TL;DR: Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and synergy with anti-oestrogens as mentioned in this paper.
1.8K
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Kimberly L. Blackwell,Fabrice Andre,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Katarína Petráková,Lowell L. Hart,Cristian Villanueva,A. Chan,Erik Jakobsen,Arnd Nusch,Olga Burdaeva,Eva-Maria Grischke,Emilio Alba,Erik Wist,Norbert Marschner,Anne Favret,Denise A. Yardley,Thomas Bachelot,Ling-Ming Tseng,Sibel Blau,Fengjuan Xuan,Farida Souami,Michelle Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +36 more
TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli,Nicholas C. Turner,Igor Bondarenko,Jungsil Ro,Seock-Ah Im,Norikazu Masuda,Marco Colleoni,Angela DeMichele,Sherene Loi,Sunil Verma,Hiroji Iwata,Nadia Harbeck,Ke Zhang,Kathy Puyana Theall,Yuqiu Jiang,Cynthia Huang Bartlett,Maria Koehler,Dennis J. Slamon +17 more
TL;DR: This study aimed to confirm the earlier findings with this extended follow-up and show the results for subgroup and biomarker analyses, and assesses endocrine therapy resistance by clinical parameters, quantitative hormone-receptor expression, and tumour PIK3CA mutational status in circulating DNA at baseline.
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz,Masakazu Toi,Mario Campone,Joohyuk Sohn,Shani Paluch-Shimon,Jens Huober,In Hae Park,Olivier Tredan,Shin-Cheh Chen,Luis Manso,Orit Freedman,Georgina Garnica Jaliffe,T. Forrester,Martin Frenzel,Susana Barriga,Ian C. Smith,Nawel Bourayou,Angelo Di Leo +17 more
TL;DR: Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
1.4K
Related Papers (5)
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Kimberly L. Blackwell,Fabrice Andre,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Katarína Petráková,Lowell L. Hart,Cristian Villanueva,A. Chan,Erik Jakobsen,Arnd Nusch,Olga Burdaeva,Eva-Maria Grischke,Emilio Alba,Erik Wist,Norbert Marschner,Anne Favret,Denise A. Yardley,Thomas Bachelot,Ling-Ming Tseng,Sibel Blau,Fengjuan Xuan,Farida Souami,Michelle Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +36 more